TriSalus Life Sciences Q3 Revenue Estimate
TriSalus Life Sciences is scheduled to report Q3'26 results on November 10 after market close. Revenue is estimated at 14.02 million USD, with EPS anticipated at (0.13) USD.
Related stories
Nordecon Signs €2.8 Million Construction Contract
Nordecon signed a building construction contract valued at €2.8 million plus VAT, with work expected to be completed in early 2028.
M impact | EQUITY | Nov 03, 2026, 02:32 PM UTC
Sotera Health Reports Quarterly Results for Period Ended September 30
Sotera Health Company reported results for the quarter ended September 30; no figures were provided.
M impact | EQUITY | Nov 03, 2026, 02:32 PM UTC
Amneal Pharmaceuticals Reports Quarterly Results Through September 30
M impact | EQUITY | Nov 03, 2026, 02:32 PM UTC
PARA: trading halted on Nasdaq — volatility pause (9:31 AM ET)
Nasdaq halted trading in PARA (volatility pause) at 9:31 AM ET.
M impact | EQUITY | Nov 03, 2026, 02:31 PM UTC
Alkermes Reports Third-Quarter Revenue of $480.1 Million, EPS of $0.09
Third-quarter revenue rose 21.8% year over year to $480.1 million, primarily reflecting LUMRYZ sales. Net income fell to $16.3 million from $82.8 million, and diluted EPS was $0.09
M impact | EQUITY | Nov 03, 2026, 02:31 PM UTC
General Electric Aerospace Shares Hit 5-week High
General Electric Aerospace shares increased to 321.44 USD, the highest since September 2026. Over the past 4 weeks, General Electric Aerospace gained 4.03%, and in the last 12 mont
L impact | EQUITY | Nov 03, 2026, 02:31 PM UTC